Last reviewed · How we verify

Atorvastatin and rosuvastatin oral solution

Merck Sharp & Dohme LLC · Phase 1 active Small molecule

Atorvastatin and rosuvastatin oral solution is a Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 1 development.

At a glance

Generic nameAtorvastatin and rosuvastatin oral solution
SponsorMerck Sharp & Dohme LLC
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Atorvastatin and rosuvastatin oral solution

What is Atorvastatin and rosuvastatin oral solution?

Atorvastatin and rosuvastatin oral solution is a Small molecule drug developed by Merck Sharp & Dohme LLC.

Who makes Atorvastatin and rosuvastatin oral solution?

Atorvastatin and rosuvastatin oral solution is developed by Merck Sharp & Dohme LLC (see full Merck Sharp & Dohme LLC pipeline at /company/merck).

What development phase is Atorvastatin and rosuvastatin oral solution in?

Atorvastatin and rosuvastatin oral solution is in Phase 1.

Related